Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world efficacy and safety of arbidol vs oseltamivir in influenza-like illness
ChiCTR2000040924Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of umifenovir in influenza-like illness (ILI) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Time to resolution of fever and Frequencies of adverse events and treatment-related adverse events. Started Dec 2020; status: recruiting.
02
Drugs
umifenovir
03
Conditions
influenza-like illness (ILI)
Beyond the preview
Go deeper on ChiCTR2000040924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040924.